OPKO Health’s (OPK) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of OPKO Health (NASDAQ:OPK) in a report published on Monday,Benzinga reports. They currently have a $3.00 target price on the biotechnology company’s stock.

Several other research firms have also weighed in on OPK. StockNews.com lowered shares of OPKO Health from a “hold” rating to a “sell” rating in a report on Wednesday, January 15th. Barrington Research reiterated an “outperform” rating and issued a $2.25 target price on shares of OPKO Health in a report on Friday, February 28th.

OPKO Health Stock Performance

OPK opened at $1.94 on Monday. The firm has a market capitalization of $1.32 billion, a PE ratio of -10.21 and a beta of 1.63. OPKO Health has a twelve month low of $0.86 and a twelve month high of $2.04. The firm’s 50-day moving average price is $1.56 and its 200 day moving average price is $1.55. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.09. The firm had revenue of $183.60 million for the quarter, compared to analyst estimates of $155.42 million. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. As a group, sell-side analysts expect that OPKO Health will post -0.25 EPS for the current fiscal year.

Insider Transactions at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost bought 67,434 shares of the company’s stock in a transaction on Friday, February 28th. The stock was purchased at an average cost of $1.71 per share, for a total transaction of $115,312.14. Following the acquisition, the chief executive officer now owns 213,301,448 shares of the company’s stock, valued at $364,745,476.08. The trade was a 0.03 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. In the last quarter, insiders bought 1,389,971 shares of company stock worth $2,124,442. Company insiders own 47.26% of the company’s stock.

Hedge Funds Weigh In On OPKO Health

Several hedge funds have recently added to or reduced their stakes in OPK. FMR LLC increased its holdings in OPKO Health by 103.6% during the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 11,089 shares in the last quarter. Orion Portfolio Solutions LLC acquired a new stake in shares of OPKO Health during the 3rd quarter worth about $45,000. Cibc World Markets Corp acquired a new stake in shares of OPKO Health during the 4th quarter worth about $45,000. Zacks Investment Management acquired a new stake in shares of OPKO Health during the 4th quarter worth about $49,000. Finally, Ieq Capital LLC acquired a new stake in shares of OPKO Health during the 4th quarter worth about $52,000. 64.63% of the stock is currently owned by hedge funds and other institutional investors.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.